News
Eli Lilly did not specify when sales of the drug would begin in China, or how many doses would be sold, according to Reuters. The drugmaker did not immediately respond to Investopedia 's request ...
Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in ...
Hosted on MSN1y
Eli Lilly weight loss drug approved in China - MSNThe Chinese drug regulator, the National Medical Products Administration (NMPA), has approved Eli Lilly’s (NYSE:LLY) weight loss therapy, tirzepatide, for long-term weight management, the ...
You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt to help with their weight loss efforts. Ozempic is actually for type-2 ...
Some analysts expect Zepound, the U.S. firm's weight-loss drug with the same active ingredient, will be approved in China this year or in the first half of 2025.
News Peg. Eli Lilly announced it will open a new $1 billion manufacturing plant in Concord, North Carolina. The plant adds to Eli Lilly’s presence in North Carolina. In 2020, the company ...
An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet ...
The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes ...
Tirzepatide is the active ingredient in Lilly’s injectable diabetes drug Mounjaro and weight-loss drug Zepbound. Mounjaro previously was approved in China for diabetes treatment.
Wegovy, the weight-loss drug developed by Novo Nordisk, was approved for sale in China, opening up a new frontier for the Danish pharmaceutical company. The firm’s stock reached a record high ...
Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk to begin selling it in the world's second-largest economy, where the appetite for similar ...
An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results